Zomedica Announces Research Agreement with Celsee Diagnostics for Cancer Liquid Biopsy ANN ARBOR, Mich., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a...

Liquid Biopsy Market Driven by Increasing Adoption in Lung Cancer Indication VALLEY COTTAGE, N.Y., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Widespread acceptance of liquid biopsy technique in North America and steady adoption in developing regions is expected to drive global liquid...

Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments -- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 ---- Growing Biomanufacturing Demand Prompts Plans for Third...

Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center --New Technology Efficiently Builds on the Company’s Existing Phosphatidylserine (PS) Targeting Platform and Assay Development Capabilities-- --Stand Alone Program That Offers Significant...